Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBioquell Regulatory News (BQE)

  • There is currently no data for BQE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

27 Aug 2010 07:00

RNS Number : 7250R
Bioquell PLC
27 August 2010
 



 

 

27 August, 2010

 

 

Bioquell PLC

Appointment of Sir Ian Carruthers OBE as a Non-Executive Director

 

Bioquell PLC (LSE: BQE) - provider of specialist low temperature, residue-free bio-decontamination technologies to the healthcare, life sciences and defence sectors - announces that Sir Ian Carruthers, OBE, has today joined the Board of Bioquell PLC as a Non Executive Director.

Sir Ian is Chief Executive of the South West Strategic Health Authority. During his 40-year NHS career Sir Ian has served in senior positions at all levels of the NHS including hospitals, community services, local and regional health authorities and as interim NHS Chief Executive.

Sir Ian's experience of the UK and international healthcare systems will help the Board of Bioquell as it develops its strategy for the future.

Commenting on the appointment, Nigel Keen, Chairman of Bioquell PLC, said:

"We are delighted that Sir Ian Carruthers, OBE, Chief Executive of the South West Strategic Health Authority, has agreed to join the Board of Bioquell as a Non Executive Director. He brings with him a wealth of experience of the UK and overseas healthcare systems which will be invaluable for the future development of the Group."

************************

 

Notes to Editors - Sir Ian Carruthers, OBE:

 

1. Sir Ian Carruthers, OBE, is Chief Executive of the South West Strategic Health Authority, which is accountable to the Department of Health for the performance of the NHS in the South West. The South West Strategic Health Authority oversees a budget of approximately £8 billion.

2. Sir Ian remains in his post as Chief Executive of the South West Strategic Health Authority and will fulfil his Non Executive role at Bioquell PLC in his own time. (Approximately one day per month). Sir Ian will receive no personal remuneration or other benefits in this role; arrangements are in place for all payment to be made to the South West Strategic Health Authority for the benefit of the NHS.

3. The South West Strategic Health Authority was formed on 1 July 2006. Sir Ian has led ambitious improvement programmes for health and healthcare. The NHS in the South West has been recognised as one of the highest performing and the most improved region in England.

4. Sir Ian has contributed to reform in the NHS over the past 30 years, including close working with the private sector. He has contributed to the development of healthcare systems both nationally and internationally.

 

Notes to editors - Bioquell PLC:

§ Bioquell is a UK-headquartered, international technology company with two divisions:

o Bio-decon which sells specialist bio-decontamination products and services into the Healthcare, Life Sciences and Defence sectors, with most of its revenues generated from overseas customers; and

o TRaC which provides specialist Testing, Regulatory and Compliance services, which are largely governed by regulations, to UK corporates.

§ Bioquell's bio-decontamination technology is principally based around hydrogen peroxide vapour - which is highly efficacious at eradicating micro-organisms such as bacteria and viruses at room temperature - and is subsequently broken down using specialist catalysts to water vapour and oxygen at the end of the bio-decontamination process.

§ Bioquell's bio-decontamination technology:

o is used to eradicate "superbugs" from hospitals; independent scientific research has demonstrated that 'bioquelling' hospital equipment and facilities reduces the rates of hospital acquired infection;

o is used by bio-pharmaceutical, biotechnology and research institutions to provide sterile equipment and/or sterile working environments;

o has been selected by the United States Department of Defense for the JSSED programme to decontaminate sensitive equipment against biological and chemical warfare agents; and

o is also used in other sectors where bioburden can create significant problems including, for example, the food industry

§ Bioquell currently has overseas operations in the USA, France, Ireland and Singapore.

§ TRaC sells its specialist services to the product development departments of a broad range of companies, principally based in the UK, with a particular focus on aerospace, military and telecoms clients.

 

Enquiries:

 

Nigel Keen Chairman Bioquell PLC 01264 835900

Nick Adams Group Chief Executive

Mark Bodeker Chief Operating Officer and Finance Director

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAPFMATMBATBRM
Date   Source Headline
30th Nov 201810:59 amRNSForm 8.3 - Bioquell
30th Nov 20187:05 amRNSOffer by Ecolab U.S. 2 Inc.
12th Nov 20184:31 pmRNSHolding(s) in Company - Replacement
9th Nov 201810:22 amRNSBlock listing Interim Review
7th Nov 20183:31 pmRNSHolding(s) in Company - Replacement
7th Nov 20189:12 amRNSHolding(s) in Company
3rd Sep 20187:47 amRNSTotal Voting Rights
1st Aug 20183:38 pmRNSTotal Voting Rights
24th Jul 20187:00 amRNSHalf-year Report
2nd Jul 20183:34 pmRNSTotal Voting Rights
11th Jun 20189:26 amRNSStatement re Block Listing Application
1st Jun 201812:02 pmRNSTotal Voting Rights
25th May 20188:05 amRNSDisposal
8th May 201810:18 amRNSBlock listing Interim Review
2nd May 201811:11 amRNSStatement re Purchase of Own Shares
1st May 20188:55 amRNSStatement re Purchase of Own Shares
30th Apr 20189:36 amRNSStatement re Purchase of Own Shares
27th Apr 20188:19 amRNSStatement re Purchase of Own Shares
26th Apr 201810:58 amRNSStatement re Purchase of Own Shares
25th Apr 20182:26 pmRNSStatement re Purchase of Own Shares
24th Apr 201810:04 amRNSStatement re Purchase of Own Shares
23rd Apr 20183:49 pmRNSResult of AGM
23rd Apr 20187:00 amRNSAGM Statement
21st Mar 20187:58 amRNSAnnual Financial Report
12th Mar 20189:13 amRNSHolding(s) in Company
7th Mar 20187:00 amRNSFinal Results
9th Jan 20187:00 amRNSTrading Statement
8th Jan 20183:39 pmRNSFurther re Disposal
2nd Jan 201811:54 amRNSTotal Voting Rights
9th Nov 201712:49 pmRNSBlock listing Interim Review
2nd Oct 20177:51 amRNSTotal Voting Rights
22nd Aug 20172:29 pmRNSDirector/PDMR Shareholding
2nd Aug 20172:08 pmRNSDisposal
26th Jul 20177:00 amRNSHalf-year Report
3rd Jul 20177:00 amRNSTotal Voting Rights
30th Jun 201712:48 pmRNSMiscellaneous replacement - Purchase of Own Shares
30th Jun 201712:45 pmRNSStatement Re Purchase of Own Shares
29th Jun 20178:59 amRNSStatement re Purchase of Own Shares
27th Jun 20179:19 amRNSStatement re Purchase of Own Shares
16th Jun 20178:35 amRNSStatement re Purchase of own shares
12th Jun 201710:39 amRNSStatement re Purchase of Own Shares
5th Jun 20178:28 amRNSStatement re Purchase of own shares
1st Jun 20171:07 pmRNSDirector/PDMR Shareholding
17th May 20174:31 pmRNSDirector/PDMR Shareholding
9th May 201710:24 amRNSBlock listing Interim Review
9th May 20178:51 amRNSStatement re Purchase of Own Shares
4th May 20173:00 pmRNSStatement re Block Listing Application
3rd May 201711:57 amRNSDirector/PDMR Shareholding
3rd May 20177:00 amRNSStatement re Share Buyback Programme
2nd May 201712:38 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.